摘要
目的:探讨血清可溶性E-选择素(sE-selectin)检测在胃癌诊治中的临床意义。方法:采用ELISA法检测200例胃癌患者、45例胃良性疾病患者和40例健康体检者血清中的可溶性E-选择素水平,比较其中140例胃癌患者手术前后血清可溶性E-选择素水平的变化,并对胃癌患者血清可溶性E-选择素、CEA、CA199和CA724的阳性率进行比较。结果:胃癌组血清可溶性E-选择素表达水平为69.12±18.19ng/mL,与正常对照组(15.85±5.27ng/mL)及良性疾病组(19.47±7.88ng/mL)比较,差异性具有统计学意义(P<0.01)。血清可溶性E-选择素阳性表达与肿瘤部位及组织学分型无明显相关(P>0.05),但与病理分期及肝转移呈正相关(P<0.05,P<0.01)。胃癌患者手术后血清可溶性E-选择素水平明显下降。胃癌患者血清可溶性E-选择素阳性率远远高于其他消化道肿瘤标物(CEA、CA199、CA724),P<0.01。结论:可溶性E-选择素有可能成为胃癌早期辅助诊断、预测复发转移及评估预后有价值的肿瘤标记物。
Objective： To study the clinical significance of serum soluble E-selectin （sE-selectin） in diagnosis and treatment of gastric cancer. Methods： Serum E-selectin was detected with ELISA in 200 cases of gastric cancer, 45 cases of benign gastric diseases and 40 healthy controls. The changes in serum sE-selectin level of 140 patients with gastric cancer were analyzed before and after surgery, and the positive ratio of sE-selectin was compared with that of CEA, CA199 and CA724 in patients with gastric cancer. Results： The level of serum sE-selectin in patients with gastric cancer was 69.12± 18.19 ng/mL, higher than that in those with benign diseases [（19.47±7.88）ng/mL] and healthy controls [（15.85±5.27）ng/mL]. The differences were significant （P〈0,01）. The level of serum sE-selectin was correlated with clinical stage and hepatic metastasis in gastric cancer patients, but was not correlated with focal location and histological grade （P〉0.05）. The positive rate of serum sE-selectin in cases with hepatic metastasis was higher than that in those without hepatic metastasis （P〈 0.01）. The level of serum sE-selectin in patients with gastric cancer declined significantly at one month after surgery. The positive rate of serum sE-selectin in patients with gastric cancer was much higher than that of other digestive tumor markers （CEA, CA199, and CA724, P〈0.01）. Conclusion： sE-selectin may be a valuable marker for early diagnosis and prognosis of gastric cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2010年第7期402-404,共3页
Chinese Journal of Clinical Oncology
